Skip to main content

Table 1 Rate of seropositivity to the four domains of PvMAS180 of vivax-infected patients and naïve controls

From: Identification of a novel merozoite surface antigen of Plasmodium vivax, PvMSA180

Domains No. of patient samples (n) Normalized MFIb 95% CId No. of healthy samples (n) Normalized MFIb 95% CId p valuee
Positive Negative Total (%)a Positive Negative Total (%)c
I 32 40 72 (44.4) 1.02 33.5–55.9 1 23 (22) 95.8 0.61 79.8–99.3 p < 0.0001
II 12 60 72 (16.7) 0.79 9.8–26.9 1 23 (22) 95.8 0.64 79.8–99.3 p < 0.01
III 29 43 72 (40.3) 1.02 29.7–51.8 1 23 (22) 95.8 0.70 79.8–99.3 p < 0.0001
IV 30 42 72 (41.7) 0.98 30.9–53.2 0 24 (24) 100 0.64 86.2–100 p < 0.0001
  1. aSeropositivity rate: percentage of positive malaria-patient samples
  2. bNormalized MFI: mean fluorescence intensities were divided by the cut-off value +2 standard deviations above the mean fluorescence intensity of the malaria-naïve samples
  3. cSero negative rate: percentage of malaria-naïve samples
  4. dConfidence intervals
  5. eDifference in the total IgG prevalence for each antigen between vivax patients and healthy individuals was calculated by the Student’s t-test. A value of P < 0.05 was considered statistically significant